There is accumulating evidence in humans and in experimental sepsis that robust activation
of the complement system occurs along with development of defects in the innate immune …

Excessive production of the complement activation product C5a appears to be harmful
during the development of sepsis in rodents. Little is known about the role of the C5a …

Introduction‐Models of sepsis‐Evidence for complement activation in sepsis‐Protective
effects of C5a generated in limited amounts‐Sepsis‐induced changes in signalling …

Sepsis is a major clinical problem for which therapeutic interventions have been largely
unsuccessful, in spite of promising strategies that were successful in animals, especially …

Complement activation products are known to be generated in the setting of both
experimental and human sepsis. C5 activation products (C5a anaphylatoxin and the …

In recent studies, evidence has been provided for complement activation early during the
onset of experimental sepsis. Excessive production of the anaphylatoxin C5a thereby …

Activation of the complement system is a key event in the pathogenesis of sepsis.
Nevertheless, the exact mechanisms remain inadequately understood. In the current study …

Sepsis is associated with extensive complement activation, compromising innate immune
defenses, especially in neutrophils (PMN). Recently, a second C5a receptor (C5L2) was …

C5a–C5aR signaling plays an essential role in innate immunity of neutrophils. However,
excessive interaction of C5a–C5aR results in harmful effects in these cells. In sepsis, robust …

Abstract At the Trauma, Shock, Inflammation and Sepsis 2007 conference, the roles of
complement activation products and relevant receptors were stressed in the setting of …